Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, shares insight on the cost-effectiveness and utility of biomarker testing in non–small cell lung cancer (NSCLC).
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, shares insight on the cost-effectiveness and utility of biomarker testing in non–small cell lung cancer (NSCLC).
Transcript
Coverage of biomarker testing has often lagged behind research advances. What should managed care leaders know about the testing landscape overall?
I think managed care companies need to understand that our job and their job should really be focused on getting the right treatment to the right patient at the right time—and that's been demonstrated to be cost-effective. Again, if you get the right treatment, you're going to have the best outcome you could possibly have.
Managed care companies need to understand the heterogeneity of [NSCLC]. This is not one-size-fits-all anymore. There are a number of different subsets of the disease that we approach very differently that the outcomes are better if you get the right treatment at the right time. So that's the message. And I think that the cost of comprehensive genomic testing is less than it used to be, and as technology improves, it will continue to decline in cost. But in the big picture of things, cost of genomic testing is miniscule compared to simply having the diagnosis and everything that comes along with it; it certainly pales in comparison to the cost of treatment in this particular setting.
I don't know why we're so hung up on the cost issue of genomic testing. It's, again, been demonstrated to be cost-effective if you get the right treatment to the right patient at the right time. That's the message, and I'm hoping that that all third-party carriers, including the managed care organizations, want the best treatment for their patients that they're covering. So I think that's the take-home message.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More